Quick Answer
Metagenomi Therapeutics, Inc. reported Net Income Loss of -$87.87 million for the year ending 2025.
- Metagenomi Therapeutics, Inc. showed a decrease of -12.6% in Net Income Loss from 2024 to 2025.
- This data is from Metagenomi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$16.13 million | Q2 2023: -$13.01 million | Q3 2023: -$19.82 million | Q1 2024: -$25.15 million | Q2 2024: -$10.74 million | Q3 2024: -$18.77 million | Q1 2025: -$25.04 million | Q2 2025: -$19.91 million | Q3 2025: -$20.39 million.
- Over the full 3 years of available data (2023 to 2025), Metagenomi Therapeutics, Inc.'s Net Income Loss has declined by 28.7%.
- Historical annual values: Fiscal year 2025: -$87.87 million | Fiscal year 2024: -$78.06 million | Fiscal year 2023: -$68.26 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: